Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026)
Zai Lab's (ZLAB) quarterly Return on Capital Employed came in at 32.72% in Q1 2026, down 154.0% year-on-year from 60.6% in Q1 2025, and down 6.9% quarter-over-quarter from 30.61% in Q4 2025.
Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026) Analysis & Trends
Zai Lab has disclosed Return on Capital Employed across 6 years of filings, most recently posting 32.72% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 32.72%, down 154.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.72% (down 154.0% YoY), and the FY2025 annual result was 30.07%, up 469.0% from the prior year.
- Return on Capital Employed came in at 32.72% for Q1 2026 at Zai Lab, down from 30.61% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.43% in Q3 2025 to a low of 48.31% in Q3 2024.
- The 5-year median for Return on Capital Employed is 36.81% (2023), against an average of 37.69%.
- Across the five-year window, Return on Capital Employed slumped 1254 bps in 2024 and jumped 1988 bps in 2025, its largest moves.
- Zai Lab's Return on Capital Employed stood at 36.12% in 2022, then dropped by 21 bps to 43.8% in 2023, then grew by 18 bps to 35.89% in 2024, then gained by 15 bps to 30.61% in 2025, then fell by 7 bps to 32.72% in 2026.
- The last three Return on Capital Employed figures came in at 32.72% (Q1 2026), 30.61% (Q4 2025), and 28.43% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Zai Lab | 20.15 Bn | 20.05 Bn | 61.30 Mn | -32.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.72% |
| Dec 31, 2025 | -30.61% |
| Sep 30, 2025 | -28.43% |
| Jun 30, 2025 | -29.50% |
| Mar 31, 2025 | -31.19% |
| Dec 31, 2024 | -35.89% |
| Sep 30, 2024 | -48.31% |
| Jun 30, 2024 | -48.08% |
| Mar 31, 2024 | -44.79% |
| Dec 31, 2023 | -43.80% |
| Sep 30, 2023 | -35.77% |
| Jun 30, 2023 | -38.30% |
| Mar 31, 2023 | -36.81% |
| Dec 31, 2022 | -36.12% |
| Sep 30, 2022 | -43.74% |
| Jun 30, 2022 | -37.25% |
| Mar 31, 2022 | -39.47% |
| Dec 31, 2021 | -47.43% |
| Sep 30, 2021 | -33.90% |
| Jun 30, 2021 | -43.14% |